Therefore, in recent decades, a lot of researchers [19–21] have paid attention to the therapeutic roles of BRAF inhibitors and MEK inhibitors (a key inhibitor of the MAPK pathway) in BRAF V600E mutant glioma. The gene discussed is MAP2K7; the disease is glioma.